CTXR - Citius Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.62
-0.04 (-1.50%)
At close: 3:14PM EDT
Stock chart is not supported by your current browser
Previous Close2.66
Open2.74
Bid2.55 x 1100
Ask3.99 x 900
Day's Range2.60 - 2.74
52 Week Range2.25 - 6.45
Volume11,859
Avg. Volume19,789
Market Cap27.974M
Beta0.01
PE Ratio (TTM)N/A
EPS (TTM)-1.72
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.50
Trade prices are not sourced from all markets
  • PR Newswireyesterday

    Citius Announces United States Patent & Trademark Office Registered the Company's Mino-Lok® Trademark

    CRANFORD, N.J., June 19, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (NASDAQ: CTXR), a specialty pharmaceutical company, announced that Mino-Lok® is now a registered trademark with the U.S. Patent and Trademark Office.  Citius' Mino-Lok® product is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs). Citius' Mino-Lok® product is intended to salvage the CVC obviating the need to remove and replace the catheter.  This is a recognized unmet medical need. "We are working towards FDA approval and commercialization of Mino-Lok, We are currently conducting a Phase 3 clinical trial and are treating patients with Mino-Lok compared to standard antibiotic lock therapies," said Mr. Myron Holubiak, CEO of Citius.  "Hopefully, we will be able to complete our trial next year and begin the NDA review process.

  • PR Newswire3 months ago

    Citius Announces $2.0 Million Registered Direct Offering Priced At-the-Market

    CRANFORD, N.J., March 29, 2018 /PRNewswire/ -- Citius Pharmaceuticals Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 669,504 shares of its common stock, at a purchase price per share of $2.9850 for gross proceeds of approximately $2.0 million, in a registered direct offering priced at-the-market. Additionally, Citius has also agreed to issue to the investors unregistered warrants to purchase up to 669,504 shares of common stock. The warrants have an exercise price of $2.86 per share, will be immediately exercisable, and will expire five and a half years from the issue date.

  • PR Newswire3 months ago

    Citius Reports Progress in Hemorroid Treatment Program

    CRANFORD, N.J., March 6, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("CITIUS") ("Company") (CTXR), a specialty pharmaceutical company, announced that the Company is selecting a higher potency corticosteroid in its steroid/anesthetic topical formulation program for the treatment of hemorrhoids. The original topical preparation, CITI-001, was a combination of hydrocortisone acetate and lidocaine hydrochloride.

  • PR Newswire4 months ago

    Citius Announces Enrollment Of First Patient In The Mino-Lok™ Phase 3 Trial

    CRANFORD, N.J., Feb. 15, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced that yesterday the first patient was randomized into the Mino-Lok Phase 3 clinical trial for catheter related bacteremias ("CRBSIs") at the Henry Ford Health System in Detroit, Michigan. Mino-Lok would be the first approved antibiotic lock for the treatment of CRBSIs.

  • PR Newswire4 months ago

    Citius Publishes Expert Roundtable Discussion On Treatment Considerations For Catheter Related Bacteremias

    SALVAGING INDWELLING CATHETERS IS ESSENTIAL WHEN THERE IS NO VASCULAR ACCESS AND THE PATIENT NEEDS LONG TERM CHRONIC PARENTERAL THERAPY CRANFORD, N.J. , Feb. 13, 2018 /PRNewswire/ -- Citius Pharmaceuticals, ...

  • PR Newswire5 months ago

    Citius Pharmaceuticals to Present at BIO CEO & Investor Conference

    CRANFORD, N.J. , Jan. 31, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, ...

  • PR Newswire5 months ago

    Citius Pharmaceuticals to Present at Biotech Showcase™ 2018

    CRANFORD, N.J. , Jan. 4, 2018 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("CTXR"), a specialty pharmaceutical company focused on adjunctive cancer care and critical care ...

  • PR Newswire6 months ago

    Citius Announces $6 Million Registered Direct Offering Priced At-the-Market

    CRANFORD, N.J., Dec. 18, 2017 /PRNewswire/ -- Citius Pharmaceuticals Inc. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase of 1,280,360 shares of its common stock, at a purchase price per share of $4.6925, for gross proceeds of approximately $6 million, in a registered direct offering priced at-the-market. Additionally, Citius has also agreed to issue to the investors unregistered warrants to purchase up to 640,180 shares of common stock. The warrants have an exercise price of $4.63 per share, will be immediately exercisable, and will expire five and a half years from the issue date.

  • PR Newswire6 months ago

    Mino-Lok™ Phase 3 Clinical Trial Supplies Shipped to Sites

    CRANFORD, N.J., Dec. 6, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, has announced that clinical trial supplies of Mino-Lok (minocycline/edetate/ethanol) have been sent to the University of Chicago Medical Center, and the Henry Ford Health System in Detroit, the first 2 clinical trial sites for the Mino-Lok phase 3 pivotal trial. When fully recruited, it is planned that there will be 50 participating sites, all located in the U.S.

  • PR Newswire7 months ago

    Citius Pharmaceuticals to Present at the 10th Annual LD Micro Invitational

    LOS ANGELES, Dec. 4, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced that it will be presenting at the 10th annual LD Micro Invitational on Wednesday, December 6th, at the Luxe Sunset Boulevard Hotel, in Los Angeles, California. Mr. Leonard Mazur, Executive Chairman of Citius, will be giving the presentation and meeting with investors.

  • PR Newswire7 months ago

    Inserting And Removing Central Venous Catheters Cause Significant Discomfort In Cancer Patients And At Times Is Unnecessary

    Use of Mino-Lok™ to disinfect CVCs could avoid patient discomfort while providing an effective alternative in the treatment of Central Line Associated Bloodstream infections (CLABSIs). CRANFORD, N.J. , ...

  • PR Newswire8 months ago

    Citius Pharmaceuticals to Present at the Dawson James 2017 Small Cap Growth Stock Conference

    CRANFORD, N.J. , Oct. 17, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. (NASDAQ: CTXR), a specialty pharmaceutical company dedicated to developing and commercializing adjunctive cancer care and critical ...

  • PR Newswire8 months ago

    Citius Pharmaceuticals Issues Shareholder Letter

    Company Highlights Recent Nasdaq Uplisting and Additional Operational Milestones CRANFORD, N.J. , Oct. 11, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (NASDAQ: ...

  • GuruFocus.com9 months ago

    Why Citius Pharmaceuticals Looks Undervalued

    Here's why the company should be trading higher than it is

  • PR Newswire9 months ago

    Citius Pharmaceuticals, Inc. Provides Phase 3 Update On Mino-Lok™ Clinical Trial Following FDA Meeting

    CRANFORD, N.J., Sept. 5, 2017 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") ("Company") (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today it has received feedback from the U. S. Food and Drug Administration regarding amendments to the phase 3 study plan for Mino-Lok™, an adjunctive treatment for catheter related blood stream infection. There are currently no approved therapies to salvage infected central venous catheters ("CVCs").  Citius is currently recruiting sites for a phase 3 trial of Mino-Lok in the United States.

  • PR Newswire10 months ago

    Citius Pharmaceuticals, Inc. Announces Closing of Public Offering

    CRANFORD, N.J., Aug. 8, 2017 /PRNewswire/ -- CITIUS PHARMACEUTICALS, INC. (CTXR),  a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, announced today the closing of its previously announced underwritten public offering of 1,648,484 shares of its common stock and warrants to purchase up to an aggregate of 1,648,484 shares of its common stock at a combined offering price of $4.125. In addition, the underwriters partially exercised the over-allotment to purchase an additional 247,272 warrants. The warrants have a per share exercise price of $4.125, are exercisable immediately and will expire five years from the date of issuance.

  • PR Newswire11 months ago

    Citius Pharmaceuticals, Inc. Prices $6,800,000 Public Offering And Listing On The Nasdaq Capital Market

    CRANFORD, N.J., Aug. 3, 2017 /PRNewswire/ -- CITIUS PHARMACEUTICALS, INC. (CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, today announced the pricing of an underwritten public offering of 1,648,484 shares of its common stock and warrants to purchase up to an aggregate of 1,648,484 shares of its common stock at a combined offering price of $4.125 per share. The warrants will have a per share exercise price of $4.125, are exercisable immediately and will expire five years from the date of issuance. The gross proceeds to Citius from this offering are expected to be approximately $6,800,000, before deducting underwriting discounts and commissions and other estimated offering expenses.